As the evidence listed in the Open Targets platform shows, GPR35 is currently investigated in clinical trials for pruritus and mastocytosis and presents a promising new therapeutic target for a number of disease indications including inflammatory and cardiovascular disease [29–33]. The gene discussed is GPR35; the disease is cardiovascular disorder.